Alex Therapeutics is a digital health company founded in 2018, dedicated to creating clinically validated companion apps that provide practical and emotional support to people living with complex conditions such as rare diseases and cancer. Their mission is to empower individuals to live confidently and thrive by addressing unique challenges related to disease and treatment management.

Established by psychologist John Drakenberg and theoretical computational molecular biophysicist Oliver Fleetwood, the company integrates psychology, technology, and personalized healthcare to change patient behavior and improve quality of life globally.

Alex Therapeutics specializes in oncology and rare diseases, delivering evidence-based digital therapeutics including AI-integrated therapy companions and cognitive behavioral therapy (CBT) based modules that support medication adherence and mental health. Their flagship product, Almee™, is a digital intervention for anxiety in pulmonary fibrosis patients with proven clinical benefits.

The company partners with pharmaceutical companies to develop customized companion apps designed to maximize drug potential and ensure compliance with global medical device regulations, such as EU MDR and FDA standards. Alex Therapeutics is ISO 27001 certified and committed to creating secure, compliant, and engaging health software solutions.

Headquartered in Stockholm, Sweden, Alex Therapeutics employs 20+ professionals across psychology, engineering, design, regulatory, and market access fields to innovate digital health solutions that improve patient outcomes worldwide.

LinkedIn: https://www.linkedin.com/company/alextherapeutics/

Official Website: https://www.alextherapeutics.com

Job Postings: Available through LinkedIn and direct contact.

Contact Email: [email protected]